Program
UTAA91
A development code. Also written as “UTAA91 injection”.
Its studies are mostly in Scleroderma, Systemic · Arthritis, Rheumatoid · Lupus Erythematosus, Systemic, led by PersonGen BioTherapeutics (Suzhou).
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PersonGen BioTherapeutics (Suzhou) | 33 open or running | early phase 1since May 6, 2025 | May 6, 2025 | Dec 2027early phase 1 · NCT06982534 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 6, 2025First studies: 3 early phase 1 studiesFirst studyNCT06970951, NCT06982547, NCT06982534
Ahead
- Dec 2027Primary completion: early phase 1 study in Arthritis, RheumatoidNCT06982547
- Dec 2027Primary completion: early phase 1 study in Scleroderma, SystemicNCT06982534
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06982547Arthritis, Rheumatoid · China | Early 1 | Not yet recruiting | Dec 2027 | 24 |
| NCT06982534Scleroderma, Systemic · China | Early 1 | Not yet recruiting | Dec 2027 | 24 |
| NCT06970951Lupus Erythematosus, Systemic · China | Early 1 | Not yet recruiting | Jun 30, 2026 | 15 |
How it is read
Names in the registry
- “UTAA91 injection”, 3 entries
Codes read as this program: UTAA91.
Conditions, from the studies’ own filings
- Scleroderma, Systemic, 1 study
- Arthritis, Rheumatoid, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.